Nursing Review Issue 2 March-April 2019 | страница 7

NEWS No link to autism MMR vaccine in the clear, study says. A new study has shown no increased risk of autism after a vaccination for measles, mumps and rubella. The 10-year cohort study of over 650,000 children “strongly supports that MMR vaccination does not increase the risk for autism, does not trigger autism in susceptible children, and is not associated with clustering of autism cases after vaccination”, wrote the authors of the paper, published in the journal Annals of Internal Medicine. Danish researchers followed 657,461 children born in Denmark from 1999 through to 31 December 2010, with follow-up from one year of age through to 31 August 2013. Of the children followed, 6517 were diagnosed with autism while they were a part of the study. Senior scientist Anders Hviid said this occurred as frequently among the children who had been vaccinated, as it did among the 31,619 children who had not. “Therefore, we can conclude that the MMR vaccine does not increase the risk of developing autism,” Hviid said. The team helped perform another large study on the issue in 2002. That also found no association between autism and the vaccine. The more recent study looked at children known to have an increased risk of developing autism themselves, such as those with siblings diagnosed with autism. Hviid said: “We also focused on other risk parameters: children with old parents, children whose mothers experienced pregnancy-related complications, children whose mothers smoked, children with low birth weight, as well as time- related associations between the time of MMR vaccination and development of autism. “In none of the cases did we observe a higher risk of developing autism among the MMR-vaccinated children compared with the non-vaccinated children.” The Danish research team, from Statens Serum Institut, added that the study results are timely because Europe is currently witnessing a tripling of measles cases in just one year. Dr Hannah Kirk from the Monash Institute of Cognitive and Clinical Neurosciences said while it’s fantastic to see another high-quality study refute the notion that there’s a link between autism and MMR vaccine, it’s disappointing that substantial research effort, time and funds continue to be directed toward disproving something “we already know to be incorrect, rather than investigating more accurate causes of autism”.  ■ 1 PBS Information: This product is listed on the National Immunisation Programme (NIP) for children only and is not listed on the PBS. Refer to the NIP Schedule. Prevenar Please review full Product Information before prescribing. Product Information is available on request on 1800 675 229 or at www.pfizer.com.au Minimum Product Information. Prevenar 13 suspension for IM injection. Indications: Active immunisation for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children from 6 weeks of age. Dose: 0.5 mL I.M. Infants 6 weeks to 6 months of age: 3 doses at least one month apart. A single booster should be given in the second year, at least 2 months after the primary series. Previously unvaccinated children: Varies with age at first dose, see full PI. Children previously vaccinated with Prevenar (7vPCV): Children 12 months to 5 years who have completed primary infant immunisation with 7vPCV and children 6 to 17 years who have received one or more doses of 7vPCV may receive 1 dose, at least 8 weeks after the final dose of 7vPCV. Adults: 1 dose. Special Populations (higher risk, e.g. HIV, SCD): 1 dose. HSCT: 4 doses. If sequential administration of Prevenar 13 and 23vPPV is considered, give Prevenar 13 first. Contraindications: Hypersensitivity to any component of the vaccine, including diphtheria toxoid. Allergic or anaphylactic reaction following prior administration of 7vPCV. Precautions: Do not administer intravenously, intravascularly, intradermally or subcutaneously. Avoid injecting into or near nerves or blood vessels. Do not inject into gluteal area. Postpone administration in acute, moderate or severe febrile illness. Only protects against Streptococcus pneumoniae serotypes included in the vaccine and may not protect all individuals from pneumococcal disease. Consider the risks of I.M injection in infants or children with thrombocytopenia or any coagulation disorder. Appropriate treatment and supervision must be readily available in case of a rare anaphylactic event. Prophylactic antipyretic medication is recommended for children receiving concomitant whole-cell pertussis vaccines, and for children with seizure disorders or history of febrile seizures. Consider the potential risk of apnoea when administering to very premature infants. Very Common/Common Adverse Effects: Children 6 weeks to 5 years: Injection site reactions (redness, pain, swelling), fever, diarrhoea, vomiting, decreased appetite, drowsiness/increased sleep; restless sleep/decreased sleep, rash, irritability. Children and adolescents 5 to 17 years: Irritability, Injection site reactions (redness, pain, swelling), somnolence, poor quality sleep, injection site tenderness (including impaired movement), fever, decreased appetite, vomiting, diarrhoea, headaches, rash. Adults: Diarrhoea, vomiting, nausea, chills, fatigue, injection site reactions (redness, pain, swelling), limitation of arm movement, fever, new or aggravated joint or muscle pain, decreased appetite, headaches, rash. Adults >65 years reported fewer adverse effects than younger adults. Adverse effects were generally most common in young adults 18 to 29 years. See full PI for details (V10516). References: 1. PREVENAR 13 ® Approved Product Information. ®Registered trademark. Pfizer Australia Pty Limited, 38–42 Wharf Road, West Ryde, NSW 2114. PP-PNA-AUS-0060. PFA2413HP/NP. 08/17. GHG PFAPRE2413 Flower Awareness Ad NurseRepb Half Page 185x133_v1_280817.indd 1 22/03/2019 10:45 AM nursingreview.com.au | 5